Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160199 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
A Phase 4 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 240
- Enrollment target
NCT00160199 is a Phase 4 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 240 participants.
The verdict
NCT00160199, a Phase 4 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 240 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
Interventions
- DRUG PROMETRIUM® 300 mg
- DRUG PROMETRIUM® 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160199
The ClinicalTrials.gov registry entry for NCT00160199 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PROMETRIUM® 300 mg is the first listed.
NCT00160199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160199 about?
NCT00160199 is a clinical study titled "Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion". To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
What is the current status of trial NCT00160199?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 240 participants. The study started on 2004-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00160199?
The interventions under investigation include: PROMETRIUM® 300 mg (DRUG), PROMETRIUM® 400 mg (DRUG).
Who is sponsoring clinical trial NCT00160199?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.